Amgen Inc. Operating Income
Amgen Inc. (AMGN) reported Operating Income of $3.51 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Amgen Inc. operating income (loss) for the quarter ending 2026-06-30 was $3.51B, a 32.30% increase year-over-year.
- Amgen Inc. operating income (loss) for the quarter ending 2026-03-31 was $2.67B, a 126.32% increase year-over-year.
- Amgen Inc. operating income (loss) for the quarter ending 2025-12-31 was $2.72B, a 17.70% increase year-over-year.
- Amgen Inc. operating income (loss) for the quarter ending 2025-09-30 was $2.53B, a 23.40% increase year-over-year.
- Amgen Inc. operating income (loss) for fiscal 2025 was $9.08B, a 25.10% increase from fiscal 2024.
- Amgen Inc. operating income (loss) for fiscal 2024 was $7.26B, a 8.09% decline from fiscal 2023.
- Amgen Inc. operating income (loss) for fiscal 2023 was $7.90B, a 17.45% decline from fiscal 2022.
- Amgen Inc. operating income (loss) for fiscal 2022 was $9.57B, a 25.23% increase from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.51B 10-Q · filed 2026-08-05 | $6.18B 10-Q · filed 2026-08-05 | $8.90B derived: sum of 3 quarters · filed 2026-08-05 | $11.43B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.67B 10-Q · filed 2026-05-01 | $5.39B derived: sum of 2 quarters · filed 2026-05-01 | $7.91B derived: sum of 3 quarters · filed 2026-05-01 | $10.57B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.72B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $5.25B derived: sum of 2 quarters · filed 2026-02-13 | $7.90B derived: sum of 3 quarters · filed 2026-08-05 | $9.08B 10-K · filed 2026-02-13 |
| 2025-09-30 | $2.53B 10-Q · filed 2025-11-05 | $5.18B derived: sum of 2 quarters · filed 2026-08-05 | $6.36B 10-Q · filed 2025-11-05 | $8.67B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.66B 10-Q · filed 2026-08-05 | $3.83B 10-Q · filed 2026-08-05 | $6.14B derived: sum of 3 quarters · filed 2026-08-05 | $8.19B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.18B 10-Q · filed 2026-05-01 | $3.49B derived: sum of 2 quarters · filed 2026-05-01 | $5.54B derived: sum of 3 quarters · filed 2026-05-01 | $7.45B derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $2.31B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $4.36B derived: sum of 2 quarters · filed 2026-02-13 | $6.27B derived: sum of 3 quarters · filed 2026-02-13 | $7.26B 10-K · filed 2026-02-13 |
| 2024-09-30 | $2.05B 10-Q · filed 2025-11-05 | $3.96B derived: sum of 2 quarters · filed 2025-11-05 | $4.95B 10-Q · filed 2025-11-05 | $6.22B derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $1.91B 10-Q · filed 2025-08-06 | $2.90B 10-Q · filed 2025-08-06 | $4.17B derived: sum of 3 quarters · filed 2026-02-13 | $6.19B derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $991.00M 10-Q · filed 2025-05-02 | $2.26B derived: sum of 2 quarters · filed 2026-02-13 | $4.28B derived: sum of 3 quarters · filed 2026-02-13 | $6.97B derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $1.27B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $3.29B derived: sum of 2 quarters · filed 2026-02-13 | $5.98B derived: sum of 3 quarters · filed 2026-02-13 | $7.90B 10-K · filed 2026-02-13 |
| 2023-09-30 | $2.02B 10-Q · filed 2024-10-31 | $4.71B derived: sum of 2 quarters · filed 2024-10-31 | $6.63B 10-Q · filed 2024-10-31 | $8.86B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $2.68B 10-Q · filed 2024-08-07 | $4.61B 10-Q · filed 2024-08-07 | $6.83B derived: sum of 3 quarters · filed 2025-02-14 | $9.49B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $1.92B 10-Q · filed 2024-05-03 | $4.15B derived: sum of 2 quarters · filed 2025-02-14 | $6.81B derived: sum of 3 quarters · filed 2025-02-14 | $8.99B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $2.23B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $4.89B derived: sum of 2 quarters · filed 2025-02-14 | $7.07B derived: sum of 3 quarters · filed 2025-02-14 | $9.57B 10-K · filed 2025-02-14 |
| 2022-09-30 | $2.66B 10-Q · filed 2023-10-31 | $4.84B derived: sum of 2 quarters · filed 2023-10-31 | $7.34B 10-Q · filed 2023-10-31 | $9.64B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $2.18B 10-Q · filed 2023-08-04 | $4.68B 10-Q · filed 2023-08-04 | $6.98B derived: sum of 3 quarters · filed 2024-02-14 | $9.36B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $2.50B 10-Q · filed 2023-04-28 | $4.80B derived: sum of 2 quarters · filed 2024-02-14 | $7.18B derived: sum of 3 quarters · filed 2024-02-14 | $8.01B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $2.30B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $4.68B derived: sum of 2 quarters · filed 2024-02-14 | $5.51B derived: sum of 3 quarters · filed 2024-02-14 | $7.64B 10-K · filed 2024-02-14 |
| 2021-09-30 | $2.38B 10-Q · filed 2022-11-04 | $3.21B derived: sum of 2 quarters · filed 2022-11-04 | $5.33B 10-Q · filed 2022-11-04 | $7.34B derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $828.00M 10-Q · filed 2022-08-05 | $2.96B 10-Q · filed 2022-08-05 | $4.96B derived: sum of 3 quarters · filed 2023-02-09 | $7.42B derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $2.13B 10-Q · filed 2022-04-28 | $4.14B derived: sum of 2 quarters · filed 2023-02-09 | $6.59B derived: sum of 3 quarters · filed 2023-02-09 | $8.91B derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $2.01B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $4.46B derived: sum of 2 quarters · filed 2023-02-09 | $6.78B derived: sum of 3 quarters · filed 2023-02-09 | $9.14B 10-K · filed 2023-02-09 |
| 2020-09-30 | $2.45B 10-Q · filed 2021-11-03 | $4.78B derived: sum of 2 quarters · filed 2021-11-03 | $7.13B 10-Q · filed 2021-11-03 | $9.18B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-30 | $2.32B 10-Q · filed 2021-08-04 | $4.68B 10-Q · filed 2021-08-04 | $6.73B derived: sum of 3 quarters · filed 2022-02-16 | $9.20B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-31 | $2.35B 10-Q · filed 2021-04-28 | $4.40B derived: sum of 2 quarters · filed 2022-02-16 | $6.88B derived: sum of 3 quarters · filed 2022-02-16 | $9.56B derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-31 | $2.05B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $4.52B derived: sum of 2 quarters · filed 2022-02-16 | $7.20B derived: sum of 3 quarters · filed 2022-02-16 | $9.67B 10-K · filed 2022-02-16 |
| 2019-09-30 | $2.48B 10-Q · filed 2020-10-29 | $5.15B derived: sum of 2 quarters · filed 2020-10-29 | $7.63B 10-Q · filed 2020-10-29 | $10.01B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $2.68B 10-Q · filed 2020-07-29 | $5.15B 10-Q · filed 2020-07-29 | $7.53B derived: sum of 3 quarters · filed 2021-02-09 | $9.86B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $2.47B 10-Q · filed 2020-05-01 | $4.85B derived: sum of 2 quarters · filed 2021-02-09 | $7.18B derived: sum of 3 quarters · filed 2021-02-09 | $10.01B derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $2.38B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $4.71B derived: sum of 2 quarters · filed 2021-02-09 | $7.54B derived: sum of 3 quarters · filed 2021-02-09 | $10.26B 10-K · filed 2021-02-09 |
| 2018-09-30 | $2.32B 10-Q · filed 2019-10-30 | $5.16B derived: sum of 2 quarters · filed 2019-10-30 | $7.88B 10-Q · filed 2019-10-30 | $10.13B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $2.83B 10-Q · filed 2019-07-31 | $5.56B 10-Q · filed 2019-07-31 | $7.80B derived: sum of 3 quarters · filed 2020-02-12 | $10.24B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $2.73B 10-Q · filed 2019-05-01 | $4.97B derived: sum of 2 quarters · filed 2020-02-12 | $7.41B derived: sum of 3 quarters · filed 2020-02-12 | $10.11B derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $2.25B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $4.68B derived: sum of 2 quarters · filed 2020-02-12 | $7.38B derived: sum of 3 quarters · filed 2020-02-12 | $9.97B 10-K · filed 2020-02-12 |
| 2017-09-30 | $2.44B 10-Q · filed 2018-10-31 | $5.14B derived: sum of 2 quarters · filed 2018-10-31 | $7.73B 10-Q · filed 2018-10-31 | $10.21B derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | $2.70B 10-Q · filed 2018-07-27 | $5.29B 10-Q · filed 2018-07-27 | $7.77B derived: sum of 3 quarters · filed 2019-02-13 | $10.30B derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $2.59B 10-Q · filed 2018-04-25 | $5.08B derived: sum of 2 quarters · filed 2019-02-13 | $7.60B derived: sum of 3 quarters · filed 2019-02-13 | $9.98B derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $2.48B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $5.01B derived: sum of 2 quarters · filed 2019-02-13 | $7.39B derived: sum of 3 quarters · filed 2019-02-13 | $9.79B 10-K · filed 2019-02-13 |
| 2016-09-30 | $2.53B 10-Q · filed 2017-10-26 | $4.91B derived: sum of 2 quarters · filed 2017-10-26 | $7.31B 10-Q · filed 2017-10-26 | $9.34B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $2.38B 10-Q · filed 2017-07-26 | $4.78B 10-Q · filed 2017-07-26 | $6.82B derived: sum of 3 quarters · filed 2018-02-13 | $9.15B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $2.40B 10-Q · filed 2017-04-27 | $4.43B derived: sum of 2 quarters · filed 2018-02-13 | $6.77B derived: sum of 3 quarters · filed 2018-02-13 | $8.85B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $2.03B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $4.37B derived: sum of 2 quarters · filed 2018-02-13 | $6.45B derived: sum of 3 quarters · filed 2018-02-13 | $8.47B 10-K · filed 2018-02-13 |
| 2015-09-30 | $2.34B 10-Q · filed 2016-10-28 | $4.42B derived: sum of 2 quarters · filed 2016-10-28 | $6.44B 10-Q · filed 2016-10-28 | $7.90B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $2.08B 10-Q · filed 2016-07-29 | $4.10B 10-Q · filed 2016-07-29 | $5.56B derived: sum of 3 quarters · filed 2017-02-14 | $7.02B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $2.02B 10-Q · filed 2016-05-02 | $3.48B derived: sum of 2 quarters · filed 2017-02-14 | $4.95B derived: sum of 3 quarters · filed 2017-02-14 | $6.85B derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $1.46B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $2.92B derived: sum of 2 quarters · filed 2017-02-14 | $4.83B derived: sum of 3 quarters · filed 2017-02-14 | $6.19B 10-K · filed 2017-02-14 |
| 2014-09-30 | $1.47B 10-Q · filed 2015-11-02 | $3.37B derived: sum of 2 quarters · filed 2015-11-02 | $4.73B 10-Q · filed 2015-11-02 | $5.92B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $1.90B 10-Q · filed 2015-08-05 | $3.27B 10-Q · filed 2015-08-05 | $4.45B derived: sum of 3 quarters · filed 2016-10-31 | $6.14B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $1.36B 10-Q · filed 2015-04-27 | $2.55B derived: sum of 2 quarters · filed 2016-10-31 | $4.24B derived: sum of 3 quarters · filed 2016-10-31 | $5.79B derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | $1.19B derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | $2.88B derived: sum of 2 quarters · filed 2016-10-31 | $4.42B derived: sum of 3 quarters · filed 2016-10-31 | $5.87B 8-K · filed 2016-10-31 |
| 2013-09-30 | $1.69B 10-Q · filed 2014-10-29 | $3.24B derived: sum of 2 quarters · filed 2014-10-29 | $4.68B 10-Q · filed 2014-10-29 | $5.77B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $1.55B 10-Q · filed 2014-08-05 | $2.99B 10-Q · filed 2014-08-05 | $4.08B derived: sum of 3 quarters · filed 2015-02-19 | $5.50B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $1.44B 10-Q · filed 2014-04-30 | $2.53B derived: sum of 2 quarters · filed 2015-02-19 | $3.95B derived: sum of 3 quarters · filed 2015-02-19 | $5.54B derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $1.09B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $2.51B derived: sum of 2 quarters · filed 2015-02-19 | $4.10B derived: sum of 3 quarters · filed 2015-02-19 | $5.58B 10-K · filed 2015-02-19 |
| 2012-09-30 | $1.42B 10-Q · filed 2013-10-29 | $3.01B derived: sum of 2 quarters · filed 2013-10-29 | $4.49B 10-Q · filed 2013-10-29 | $5.65B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $1.59B 10-Q · filed 2013-08-06 | $3.07B 10-Q · filed 2013-08-06 | $4.23B derived: sum of 3 quarters · filed 2014-02-24 | $4.75B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | $1.48B 10-Q · filed 2013-05-03 | $2.64B derived: sum of 2 quarters · filed 2014-02-24 | $3.16B derived: sum of 3 quarters · filed 2014-02-24 | $4.50B derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $1.16B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $1.69B derived: sum of 2 quarters · filed 2014-02-24 | $3.02B derived: sum of 3 quarters · filed 2014-02-24 | $4.31B 10-K · filed 2014-02-24 |
| 2011-09-30 | $525.00M 10-Q · filed 2012-11-06 | $1.86B derived: sum of 2 quarters · filed 2012-11-06 | $3.15B 10-Q · filed 2012-11-06 | $4.22B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $1.33B 10-Q · filed 2012-08-08 | $2.63B 10-Q · filed 2012-08-08 | $3.69B derived: sum of 3 quarters · filed 2013-02-27 | $5.17B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $1.29B 10-Q · filed 2012-05-08 | $2.36B derived: sum of 2 quarters · filed 2013-02-27 | $3.84B derived: sum of 3 quarters · filed 2013-02-27 | $5.36B derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $1.07B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $2.55B derived: sum of 2 quarters · filed 2013-02-27 | $4.06B derived: sum of 3 quarters · filed 2013-02-27 | $5.54B 10-K · filed 2013-02-27 |
| 2010-09-30 | $1.48B 10-Q · filed 2011-11-04 | $3.00B derived: sum of 2 quarters · filed 2011-11-04 | $4.48B 10-Q · filed 2011-11-04 | $5.60B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $1.52B 10-Q · filed 2011-08-08 | $3.00B 10-Q · filed 2011-08-08 | $4.12B derived: sum of 3 quarters · filed 2012-02-29 | $5.73B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $1.48B 10-Q · filed 2011-05-10 | $2.60B derived: sum of 2 quarters · filed 2012-02-29 | $4.21B derived: sum of 3 quarters · filed 2012-02-29 | $5.67B derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $1.12B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $2.73B derived: sum of 2 quarters · filed 2012-02-29 | $4.18B derived: sum of 3 quarters · filed 2012-02-29 | $5.51B 10-K · filed 2012-02-29 |
| 2009-09-30 | $1.60B 10-Q · filed 2010-11-08 | $3.06B derived: sum of 2 quarters · filed 2010-11-08 | $4.38B 10-Q · filed 2010-11-08 | $5.52B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-06-30 | $1.46B 10-Q · filed 2010-08-09 | $2.78B 10-Q · filed 2010-08-09 | $3.92B derived: sum of 3 quarters · filed 2011-02-25 | $5.40B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-03-31 | $1.32B 10-Q · filed 2010-05-07 | $2.46B derived: sum of 2 quarters · filed 2011-02-25 | $3.94B derived: sum of 3 quarters · filed 2011-02-25 | $5.12B derived: sum of 4 quarters · filed 2011-02-25 |
| 2008-12-31 | $1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $2.62B derived: sum of 2 quarters · filed 2011-02-25 | $3.80B derived: sum of 3 quarters · filed 2011-02-25 | $5.21B 10-K · filed 2011-02-25 |
| 2008-09-30 | $1.48B 10-Q · filed 2009-11-06 | $2.66B derived: sum of 2 quarters · filed 2009-11-06 | $4.08B 10-Q · filed 2009-11-06 | |
| 2008-06-30 | $1.18B 10-Q · filed 2009-08-10 | $2.59B 10-Q · filed 2009-08-10 | ||
| 2007-12-31 | $3.98B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |